Even though we have shown in vivo that an LXR agonist can reduce tumor growth by inducing LXRβ, pannexin 1, and NLRP3-dependent caspase-1 activation specifically in tumor cells, further investigations will be necessary to elucidate the precise interaction between pyroptosis of tumor cells and the immune system and to determine whether LXR agonists could induce immunogenic cell death. The gene discussed is CASP1; the disease is neoplasm.